Drugs / TISSEEL VH fibrin sealant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00161733 | Sep 2002 → Nov 2004 | — | Baxter Healthcare Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TISSEEL VH fibrin sealant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00161733 ↗ |
| Known as | Tisseel VH | “FS VH S/D or Tisseel VH are applied” NCT00161733 ↗ |
| Modality | Protein / enzyme biologic | “TISSEEL VH fibrin sealant” NCT00161733 ↗ |
| Route | Topical | “FS VH S/D or Tisseel VH are applied” NCT00161733 ↗ |